<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439540</url>
  </required_header>
  <id_info>
    <org_study_id>1104/16</org_study_id>
    <nct_id>NCT03439540</nct_id>
  </id_info>
  <brief_title>Influence of Plantago Major on Mineral Metabolism and Selected Biochemical Parameters in Obese Women</brief_title>
  <acronym>Plantago</acronym>
  <official_title>The Study on the Influence of Plantago Species (Plantago Major) on Adipose Tissue Content, Mineral Metabolism and Other Selected Biochemical Parameters of Blood in Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of oral supplementation with Plantago major on cardiometabolic risk factors and&#xD;
      mineral content and lifestyle in obese women: double-blind, randomized clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine whether oral Plantago major supplementation affects&#xD;
      cardiometabolic risk factors, mineral content, and lifestyle in obese women.&#xD;
&#xD;
      In previous research it was found that the Plantago maxima extract counteracts the&#xD;
      development of adipose tissue in rats on a high-fat diet. In addition, antioxidative,&#xD;
      anti-inflammatory and antidiabetic action of Plantago has been demonstrated. Moreover, it has&#xD;
      been shown that Plantago influences lipolysis in obese mice and ameliorates metabolic&#xD;
      processess in obese rats.&#xD;
&#xD;
      The project is due to evaluate the effect of oral supplementation with selected Plantago&#xD;
      species - Plantago major in obese patients on:&#xD;
&#xD;
        -  the content of minerals in blood, hair and urine&#xD;
&#xD;
        -  total cholesterol, HDL and LDL cholesterol and triglycerides blood concentration,&#xD;
&#xD;
        -  blood glucose and insulin concentration,&#xD;
&#xD;
        -  blood pressure,&#xD;
&#xD;
        -  anthropometric parameters: body mass, body height, waist and hip circumferences&#xD;
&#xD;
        -  body content measured by bioimpedance: % of fat tissue and % of muscle tissue&#xD;
&#xD;
        -  quality of life&#xD;
&#xD;
           70 subjects will be randomized into two groups and receive oral Plantago major extract&#xD;
           (the first group) or oral placebo (the second group) once daily for 12 weeks. At&#xD;
           baseline and at completion (after 12 weeks) fasting blood, urine and hair samples will&#xD;
           be collected and abovementioned parameters will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mineral content</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>content of minerals in serum, urine and hair</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>body mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body height</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>body height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hip circumference</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body content measured by bioimpedance: % of fat tissue</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Content of fat tissue measured by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body content measured by bioimpedance: % of muscle tissue</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Content of muscle tissue measured by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum total cholesterol</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Serum concentration of total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum LDL cholesterol</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Serum concentration of LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum HDL cholesterol</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Serum concentration of HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum triglycerides</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>Serum concentration of triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>insulin serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose</measure>
    <time_frame>At the baseline and following 12 weeks of treatment</time_frame>
    <description>glucose serum concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals receive a placebo daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plantago major</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals receive Plantago major daily, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plantago major</intervention_name>
    <description>Individuals receive Plantago major daily, for 12 weeks</description>
    <arm_group_label>Plantago major</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Individuals receive placebo daily, for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index (BMI) equal to or greater than 30 kg/m2&#xD;
&#xD;
               -  age 18 to 60 years&#xD;
&#xD;
               -  stable body weight (&lt; 3 kg self-reported change during the previous three months)&#xD;
&#xD;
               -  written informed consent to participate in the study,&#xD;
&#xD;
               -  abdominal obesity - waist circumference&gt; 80 cm;&#xD;
&#xD;
               -  body fat content measured by bio-impedance ≥ 33%;&#xD;
&#xD;
               -  female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary obesity or secondary hypertension&#xD;
&#xD;
          -  diabetes type I&#xD;
&#xD;
          -  gastrointestinal disease;&#xD;
&#xD;
          -  dyslipidaemia, type 2 diabetes, hypertension requiring the implementation of&#xD;
             pharmacological treatment in the last 3 months prior to observation or follow-up;&#xD;
&#xD;
          -  a history of use of any dietary supplements within the one month prior to the study&#xD;
&#xD;
          -  clinically significant acute or chronic inflammatory disease in the respiratory,&#xD;
             gastrointestinal or genitourinary system or in the mouth, throat, paranasal sinuses&#xD;
             and / or connective tissue disease, arthritis;&#xD;
&#xD;
          -  simultaneous participation in a study that affects body mass or use of diet /&#xD;
             medication / nutritional behaviors affecting body mass;&#xD;
&#xD;
          -  a history of infection in the month prior to the study&#xD;
&#xD;
          -  nicotine, drug or alcohol abuse&#xD;
&#xD;
          -  or other condition that, in the opinion of the investigators, would make participation&#xD;
             not in the best interest of the patient or could prevent, limit, or confound the study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Suliburska, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Suliburska, Assoc. Prof.</last_name>
    <phone>+48 618487334</phone>
    <email>jsulibur@up.poznan.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Poznan University of Life Sciences</name>
      <address>
        <city>Poznań</city>
        <zip>60-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Suliburska, Assoc. Prof.</last_name>
      <phone>+48 618487334</phone>
      <email>jsulibur@up.poznan.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Life Sciences</investigator_affiliation>
    <investigator_full_name>Joanna Suliburska</investigator_full_name>
    <investigator_title>assiastant professor</investigator_title>
  </responsible_party>
  <keyword>Plantago major</keyword>
  <keyword>obesity</keyword>
  <keyword>mineral content</keyword>
  <keyword>adipose tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

